HLS Therapeutics (TSE:HLS) Trading 1.1% Higher - Should You Buy?

Shares of HLS Therapeutics Inc. (TSE:HLS - Get Free Report) were up 1.1% during mid-day trading on Friday . The company traded as high as C$4.72 and last traded at C$4.65. Approximately 3,600 shares changed hands during mid-day trading, a decline of 75% from the average daily volume of 14,306 shares. The stock had previously closed at C$4.60.

Wall Street Analyst Weigh In

Separately, Stifel Nicolaus upped their price objective on shares of HLS Therapeutics from C$3.50 to C$4.00 and gave the stock a "hold" rating in a research report on Wednesday, March 26th.

HLS Therapeutics Stock Up 4.0%

The company has a market cap of C$104.12 million, a P/E ratio of -4.69 and a beta of 1.07. The company has a debt-to-equity ratio of 86.50, a quick ratio of 1.01 and a current ratio of 1.56. The stock has a 50-day moving average of C$4.29 and a two-hundred day moving average of C$3.97.

HLS Therapeutics Company Profile

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris.